Newtyn Management, LLC Phathom Pharmaceuticals, Inc. Transaction History

Newtyn Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$6.21 - $11.05 $2.99 Million - $5.32 Million	-481,760 Reduced 74.49%	165,000 $1.75 Million
Q4 2023 Feb 14, 2024	BUY	$6.99 - $10.71 $1.03 Million - $1.57 Million	146,760 Added 29.35%	646,760 $5.9 Million
Q3 2023 Nov 14, 2023	SELL	$10.26 - $15.7 $1.88 Million - $2.88 Million	-183,648 Reduced 26.86%	500,000 $5.19 Million
Q2 2023 Aug 14, 2023	BUY	$7.28 - $14.32 $11,800 - $23,212	1,621 Added 0.24%	683,648 $9.79 Million
Q1 2023 May 15, 2023	BUY	$6.19 - $12.36 $1.23 Million - $2.45 Million	197,953 Added 40.89%	682,027 $4.87 Million
Q4 2022 Feb 14, 2023	BUY	$9.18 - $11.53 $1.54 Million - $1.94 Million	168,099 Added 53.2%	484,074 $5.43 Million
Q3 2022 Nov 14, 2022	BUY	$6.46 - $12.11 $388,943 - $729,118	60,208 Added 23.54%	315,975 $3.5 Million
Q2 2022 Aug 15, 2022	BUY	$6.2 - $15.5 $1.59 Million - $3.96 Million	255,767 New	255,767 $2.16 Million

144

73.6M

42.3K

45.7K

Ticker PHAT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,175,200
Market Cap $292M
Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...

Get notified when there are updates to the investment portfolio of Newtyn Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Newtyn Management, LLC with notifications on news.